PCN26 PHARMACOECONOMIC ANALYSIS IN SPAIN OF THERAPY WITH ERLOTINIB, DOCETAXEL, PEMETREXED OR BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER WHO HAVE FAILED PREVIOUS CHEMOTHERAPY REGIMENS
Abstract
Authors
C Rubio Terres C Alvarez Sanz GM Marlene Gylmark